Arseus

Arseus NV (formerly), now Fagron
Public company[1]
Traded as RCUS.BR on the Brussels Stock Exchange
Industry Healthcare services and products
Predecessor Omega Pharma (Professional health division)
Headquarters Rotterdam, Netherlands[2]
Area served
 Europe, South America and the United States[3]
Number of employees
 over 2,000[2]
Website www.arseus.com/en/

Arseus NV is a publicly traded multinational group of companies governed by Belgian law. Its registered office is located in Waregem, Belgium, and its headquarters is located at Rotterdam, Netherlands.[2] Arseus was formerly the Professional Health Division of Omega Pharma, and became an independent entity via an IPO on October 5, 2007 and has been listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam since then. Its share is included in the BEL MID-index and the Amsterdam Small Cap Index (AScX). The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam (the Netherlands). Since January 2015, the Group has been renamed Fagron.

Overview

Arseus supplies products and services to professionals and institutions in the healthcare sector in Europe, the United States, Brazil and Argentina. The company comprises four company divisions:

Fagron was founded in Rotterdam (the Netherlands) in 1990 by Ger van Jeveren, the current CEO of the Fagron Group. Fagron is currently active in 29 countries in Europe, Africa, the Americas, Asia and the Pacific. Fagron products are sold to 150,000 customers in over 55 countries around the world. With 1,500 employees, Fagron generated a turnover of US$ 400 million in 2012.

Pharmaceutical compounding - the creation and dispensing of tailor-made medications - is the root of the pharmacy profession often symbolised by the mortar and pestle. Compounding allows the pharmacist to work with the patient and the prescriber to customise medication to meet the patient’s specific needs. It regularly happens, for example, that patients need their medication in a dosage form or strength that is not available or that patients are allergic to an ingredient. In such situations, pharmaceutical compounding provides a tailor-made solution for the patient.

References

  1. ↑ "Arseus goes public" (in Dutch). Brabantsdagblad.nl. October 3, 2007. Retrieved 2012-05-20. (subscription required)
  2. 1 2 3 "Our company: Profile". arseus.com. Retrieved May 19, 2012.
  3. 1 2 3 4 5 "Profile: Arseus NV (RCUS.BR)". in.reuters.com. Retrieved May 19, 2012.

Further reading

External links

This article is issued from Wikipedia - version of the Wednesday, May 04, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.